FDA Clearance Tracker · P180011
Eluvia Drug-Eluting Vascular Stent System
Last checked: Nov 20, 2026Latest source record: Sep 18, 2018 (this decision)Source: openFDAMethods & limitations
Decided
Sep 18, 2018
Approved
Time to decision
158 days
Received Apr 13, 2018. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P180011
- Device name
- Eluvia Drug-Eluting Vascular Stent System
- Applicant
- Boston Scientific Corp
- Applicant location
- Maple Grove, MN
- Received
- Apr 13, 2018
- Decided
- Sep 18, 2018
- Decision
- Approved
- Supplements
- 67 in FDA's data for this PMA. See them on the FDA record
Device type
- Device class
- Class III
- Specialty
- CardiologyInterventional Cardiology
FDA's approval statement
As written in FDA's record.
Approval for the ELUVIA Drug-Eluting Vascular Stent System. The device is indicated for improving luminal diameter in the treatment of symptomatic de-novo or restenotic lesions in the native superficial femoral artery (SFA) and/or proximal popliteal artery with reference vessel diameters (RVD) ranging from 4.0 - 6.0 mm and total lesion lengths up to 190 mm.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code NIU. The earliest in FDA's data is P100022, decided Nov 14, 2012.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Boston Scientific Corp
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P130030 · Decided Mar 10, 2026 · 4,453 days after receipt
Device type: STENT, CORONARY (MAF) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.